琥珀酸他舒格替尼全网公布的2025年最新价格

Tasugatinib succinate is a targeted drug for biliary tract cancer with specific gene mutations. Its latest price, efficacy and contraindication population information in 2025 is crucial to patients and the medical community. After the drug was launched in Japan, it attracted widespread attention due to its unique mechanism of action and significant clinical effects.

The latest price of tasugatinib succinate in 2025 announced on the entire website

It is produced by Japan Eisai Co., Ltd., and the specification is 35mg*56 tablets per box. According to the latest information published on the Internet in 2025, the price of the drug in the Japanese market is approximately US$7,131 per box. This price is undoubtedly a huge financial burden for most patients.

Price composition and influencing factors

The high price of tasugatinib succinate is mainly due to its research and development costs, production technology and market positioning. Its research and development process involves a large number of clinical trials and scientific research, which require huge financial investment. In addition, the drug's production process is complex and requires high raw materials and production equipment, which further drives up its cost.

Price change trends and future prospects

As the pharmaceutical market continues to develop and competition intensifies, the price of tasugatinib succinate may fluctuate to some extent in the future. No matter how the price changes, patients should use drugs rationally under the guidance of doctors and avoid blindly pursuing low-priced drugs while ignoring their efficacy and safety.

The efficacy of tasugatinib succinate

As a fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor, tasugatinib succinate inhibits tumor growth by inhibiting the phosphorylation of FGFR fusion proteins and the phosphorylation of downstream signaling molecules. The drug has demonstrated significant clinical efficacy in the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusion or rearrangement that progressed after chemotherapy.

Clinical trial data

According to clinical trial data, patients treated with tasugatinib succinate had a higher objective response rate, exceeding the preset tumor response threshold and achieving statistical significance. The drug can significantly reduce the size of patients' tumors and improve their quality of life.

Durability of efficacy and safety

In addition to the significant objective response rate, tasugatinib succinate also demonstrated good durability and safety of efficacy. In clinical trials, most patients were able to tolerate treatment with the drug, and adverse reactions were relatively controllable.

Contraindicated groups for tasugatinib succinate

Although tasugatinib succinate has demonstrated significant clinical effects in the treatment of specific gene-mutated biliary tract cancers, not all patients are suitable for the drug.

Pregnant and lactating women

Pregnant women or women who may be pregnant need to be particularly cautious when using tasugatinib succinate. Pregnant women or women who may be pregnant should only consider using this drug when they judge that the benefits of treatment outweigh the risks. At the same time, breastfeeding women should also avoid using this drug because the drug may be passed to the baby through breast milk, causing serious adverse reactions in the baby.

Children and patients with impaired hepatic function

There have been no clinical trials of tasugatinib succinate in pediatric patients, so the safety and effectiveness of this drug in children is unknown. For pediatric patients, physicians should carefully assess their condition and needs and pursue other treatment options if necessary.

In addition, because tasugatinib succinate is mainly metabolized in the liver, patients with impaired liver function need to be particularly cautious when using this drug to avoid increased blood concentrations due to slowed drug metabolism and increased risk of adverse reactions.